Navigation Links
YM BioSciences reports second quarter 2010 operational and financial results
Date:2/8/2010

the Company acquired Cytopia, a clinical-stage, drug development company, based in Melbourne, Australia. This transaction was conducted by a Scheme of Arrangement whereby Cytopia shareholders received 0.0852 YM shares for each Cytopia share held at the record date. This resulted in the issuance of 7,215,053 YM common shares in exchange for Cytopia common shares and 61,635 YM common shares plus 138,442 YM stock options in exchange for the Partly Paid shares of Cytopia. In addition, the Company issued 225,950 stock options in consideration for the cancellation of Cytopia stock options. Based on the closing price of YM shares on the TSX on January 29, the value of the transaction was approximately $12.6 million, the total number of YM common shares outstanding as of this date was 65,604,476 and market capitalization of the Company was approximately $112.8 million at closing.

Financial Results (CDN dollars)

Total revenue for the second quarter of fiscal 2010, ended December 31, 2009 was $0.7 million compared to $2.2 million for the second quarter of fiscal 2009, ended December 31, 2008. Total revenue for the first six months of fiscal 2010, ended December 31, 2009 was $1.5 million compared with $3.9 million for the first six months of fiscal 2009, ended December 31, 2008. Revenue from licensees was $0.7 million for second quarter of fiscal 2010 compared to $1.8 million for the second quarter of fiscal 2009. Revenue from licensees for the first six months of fiscal 2010, ended December 31, 2009'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Neurocrine Biosciences Announces the Appointment of William H. Rastetter to Its Board of Directors
2. Sangamo BioSciences Reports Fourth Quarter and Full Year 2009 Financial Results
3. Sangamo BioSciences Announces Presentation at BIO CEO & Investor Conference
4. Cellectricon Files Patent Infringement Suit Against Fluxion Biosciences
5. YM BioSciences announces FDA clearance for two ongoing Phase II nimotuzumab trials into USA
6. YM BioSciences announces result of Cytopia shareholder vote
7. Profectus Biosciences to Present at Key Investor Conference in January 2010
8. David L. Macdonald Appointed CEO of GeneLink BioSciences, Inc.
9. YM BioSciences Inc. and Therapure Biopharma Inc. Announce Contract
10. Nu-Tek BioSciences, LLC. Launches Animal-Free, Non-GM Soy Peptone
11. Cardio3 BioSciences Completes Patient Enrolment in First Stage of Pivotal Trial of C-Cure(R) in Heart Failure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2014)... MediVet America and NanoFiber Veterinary combined ... the specialized Wolvega Horse Clinic. , Due to a ... ruptured 90% and her deep digital flexor tendon 50%. ... for a horse. , The clinic has performed numerous ... This revolutionary regenerative option for ruptured tendons has only ...
(Date:9/19/2014)... use light, rather than electricity, to move data ... efficiency is a growing concern as chips, transistor ... of optical circuits light emitters, modulators, and ... One promising light source for optical chips is ... when deposited as a single, atom-thick layer. Other ...
(Date:9/19/2014)... 2014  Nektar Therapeutics (NASDAQ: NKTR ... the analgesic profiles of a series of the ... molecules. The preclinical research candidates were created using ... The analgesic properties of kappa receptor agonism ... Kappa opioid receptors are expressed in the ...
(Date:9/19/2014)... Minnesota (PRWEB) September 19, 2014 ... related food industries will gather October 5–8, 2014, ... the Rhode Island Convention Center in Providence, Rhode ... feature the work of food scientists, chemists, microbiologists, ... control, and food production management. To date, 1,000 ...
Breaking Biology Technology:World’s first tendon replacement using Nanofiber and activated MediVet Stem Cell Fraction 2World’s first tendon replacement using Nanofiber and activated MediVet Stem Cell Fraction 3Toward optical chips 2Toward optical chips 3Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 2Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 3Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 4Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 5Latest Research on Cereal Grain Quality, Health Benefits and Food Production to be Presented During the AACC International Annual Meeting 2Latest Research on Cereal Grain Quality, Health Benefits and Food Production to be Presented During the AACC International Annual Meeting 3
... REYKJAVIK, Iceland, August 10 deCODE genetics,(Nasdaq: ... the,quarter ended June 30, 2009. A conference call to ... will be webcast live tomorrow,Tuesday, August 11, at 8:00am ... , The financial results presented ...
... BOZEN, Italy, August 10 , ... Health Robotics today announced that it has signed ... Robot. The,agreement enables McKesson to achieve its goal of safely, ... "We are very pleased to have ...
... 10 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY ) ... sale of approximately 2.28 million shares of its common stock ... stock for gross proceeds of approximately $15.0 million on August ... per unit (each unit consisting of one share and a ...
Cached Biology Technology:deCODE genetics Announces Second Quarter 2009 Financial Results 2deCODE genetics Announces Second Quarter 2009 Financial Results 3deCODE genetics Announces Second Quarter 2009 Financial Results 4deCODE genetics Announces Second Quarter 2009 Financial Results 5deCODE genetics Announces Second Quarter 2009 Financial Results 6deCODE genetics Announces Second Quarter 2009 Financial Results 7deCODE genetics Announces Second Quarter 2009 Financial Results 8deCODE genetics Announces Second Quarter 2009 Financial Results 9deCODE genetics Announces Second Quarter 2009 Financial Results 10McKesson Expands Pharmacy Automation Product Portfolio to Include I.V. Therapy 2McKesson Expands Pharmacy Automation Product Portfolio to Include I.V. Therapy 3Oncothyreon announces closing of $15.0 million registered direct financing 2
(Date:9/18/2014)... it that when people are too stressed they are ... the Brain Mind Institute (BMI) at EPFL have just ... between chronic stress and the loss of social skills ... attacks a synaptic regulatory molecule in the brain. This ... Communications . , Carmen Sandi,s team went to ...
(Date:9/18/2014)... ultimate form of camouflage: you don,t just blend in, ... not as uncommon as you might think. Kathryn Feller, ... that the larval life stages of many marine species ... anatomy that most creatures cannot make transparent. Feller explains ... each individual eye unit with an opaque pigment to ...
(Date:9/18/2014)... spend their entire lives nestling in the protective tentacles ... babies they sometimes travel hundreds of kilometres across the ... reef fish has been predicted, this is the first ... distant populations has been observed. , Dr Steve Simpson, ... the University of Exeter, and colleagues from the Australian ...
Breaking Biology News(10 mins):How stress tears us apart 2Transparent larvae hide opaque eyes behind reflections 2Expedition finds Nemo can travel great distances to connect populations 2Expedition finds Nemo can travel great distances to connect populations 3
... professors are leading research teams that will work ... and the Caribbean to increase food production, improve ... change. The projects are part of the Sustainable ... Program (SANREM CRSP), a $15 million, five-year program ...
... study from Children,s Hospital Boston and the Boston-based Autism Consortium ... known as chromosomal microarray analysis, has about three times the ... (ASDs) than standard tests. Publishing in the April issue of ... that CMA become part of the first-line genetic work-up for ...
... WINSTON-SALEM, N.C. Vitamin D is quickly becoming the "go-to" ... to atherosclerosis. However, new evidence from a Wake Forest University ... those with low levels may have different effects based on ... do harm. The study is the first to ...
Cached Biology News:Researchers introducing sustainable agriculture practices to improve food security 2Researchers introducing sustainable agriculture practices to improve food security 3A better genetic test for autism 2A better genetic test for autism 3Vitamin D levels have different effects on atherosclerosis in blacks and whites 2Vitamin D levels have different effects on atherosclerosis in blacks and whites 3
quantitation of phosphatase activity, evaluation of hits and leads from HTS...
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
Request Info...
... Protocol Development ,Probe Titer and ... DNA Screenings in Animal or ... Labeling of RNA / Protein ... and DNA Localization in Transgenic ...
Biology Products: